FY2010 RESULTS PRESENTATION



March 4, 2011

Disclaimer

IMPORTANT: YOU MUST READ THE FOLLOWING BEFORE CONTINUING.

THE FOLLOWING APPLIES TO THE COMPANY PRESENTATION (THE "COMPANY PRESENTATION") FOLLOWING THIS IMPORTANT NOTICE, AND YOU ARE THEREFORE ADVISED TO READ THIS IMPORTANT NOTICE CAREFULLY BEFORE READING, ACCESSING OR MAKING ANY OTHER USE OF THE COMPANY PRESENTATION, YOU AGREE TO BE BOUND BY THE FOLLOWING TERMS AND CONDITIONS, INCLUDING ANY MODIFICATIONS TO THEM ANY TIME THAT YOU RECEIVE ANY INFORMATION FROM US AS A RESULT OF SUCH ACCESS. THE INFORMATION CONTAINED IN THIS COMPANY PRESENTATION HAS BEEN PREPARED BY AVANGARDCO INVESTMENTS PUBLIC LIMITED ("AVANGARD" OR THE "COMPANY").

THIS COMPANY PRESENTATION DOES NOT CONSTITUTE OR FORM A PART OF, AND SHOULD NOT BE CONSTRUED AS, (A) AN ADVERTISEMENT OF ANY SECURITIES OF THE COMPANY, OR AN OFFER, OR AN INVITATION (INCLUDING AN INVITATION TO MAKE AN OFFER) BY OR ON BEHALF OF THE COMPANY TO SUBSCRIBE FOR, OR TO PURCHASE, ANY SECURITIES OF THE COMPANY OR AN ADVERTISEMENT FOR SECURITIES IN UKRAINE OR (B) ANY PROMISE OR REPRESENTATION THAT ANY SUCH OFFER OR INVITATION WILL BE MADE AND SHALL NOT FORM THE BASIS OF, NOR MAY IT ACCOMPANY, NOR FORM PART OF, ANY CONTRACT TO ACQUIRTIES OF THE COMPANY IN UKRAINE OR IN ANY OTHER JURISDICTION.

THIS DOCUMENT DOES NOT CONTAIN OR CONSTITUTE AN OFFER OF, OR THE SOLICITATION OF AN OFFER TO BUY OR SUBSCRIBE FOR, SECURITIES TO ANY PERSON IN AUSTRALIA, CANADA, JAPAN, UKRAINE OR THE UNITED STATES OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. THE SECURITIES ACT.") OR ANOTHER EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT.") OR ANOTHER EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN AUSTRALIA, CANADA, JAPAN, OR UKRAINE OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA, JAPAN, OR UKRAINE. THE OFFER AND SALE OF THE SECURITIES REFERRED TO HEREIN HAS NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES IN THE UNITED STATES.

THIS COMPANY PRESENTATION IS ONLY ADDRESSED TO AND DIRECTED AT PERSONS IN MEMBER STATES OF THE EUROPEAN ECONOMIC AREA WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF ARTICLE 2(1)(E) OF THE PROSPECTUS DIRECTIVE (DIRECTIVE 2003/71/EC) ("QUALIFIED INVESTORS"). IN ADDITION, IN THE UNITED KINGDOM, THIS COMPANY PRESENTATION IS BEING DISTRIBUTED ONLY TO, AND IS DIRECTED ONLY AT (I) INVESTMENT PROFESSIONALS WITHIN THE MEANING SET OUT IN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER") AND QUALIFIED INVESTORS FALLING WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (II) PERSONS TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THIS COMPANY PRESENTATION MUST NOT BE ACTED ON RELIED ON (I) IN THE UNITED KINGDOM, BY PERSONS WHO ARE NOT RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OTHER THAN THE UNITED KINGDOM, BY PERSONS WHO ARE NOT QUALIFIED INVESTORS. AND WILL BE ENGAGED IN ONLY STORS. AND WILL BE ENGAGED IN ONLY MITHS COMPANY PRESENTATION RELATES IS AVAILABLE ONLY TO (I) IN THE UNITED KINGDOM, RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OTHER THAN THE UNITED KINGDOM, RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OTHER THAN THE UNITED KINGDOM, RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OTHER THAN THE UNITED KINGDOM, RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OTHER THAN THE UNITED KINGDOM, RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OTHER THAN THE UNITED KINGDOM, RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OTHER THAN THE UNITED KINGDOM, RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OTHER THAN THE UNITED KINGDOM, RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OTHER THAN THE UNITED KINGDOM, RELEVAN

THIS COMPANY PRESENTATION MAY NOT BE USED IN ANY JURISDICTION WHERE SUCH USE IS NOT AUTHORISED OR IS UNLAWFUL. THE DISTRIBUTION OF THIS COMPANY PRESENTATION IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. PERSONS IN WHOSE POSSESSION THIS COMPANY PRESENTATION MAY COME ARE REQUIRED TO INFORM THEMSELVES ABOUT AND TO OBSERVE SUCH RESTRICTIONS.

EACH RECIPIENT HEREOF, BY VIRTUE OF RECEIVING THIS COMPANY PRESENTATION, WILL BE DEEMED TO HAVE ACKNOWLEDGED, REPRESENTED AND AGREED THAT IT IS NOT A U.S. PERSON AND IS ACTING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A NON U.S. PERSON IN AN OFFSHORE TRANSACTION (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) AND (A) IF IT IS IN THE UNITED KINGDOM, IT IS A RELEVANT PERSON, AND/OR A RELEVANT PERSON WHO IS ACTING ON BEHALF OF, RELEVANT PERSONS IN THE UNITED KINGDOM AND/OR QUALIFIED INVESTORS TO THE EXTENT IT IS ACTING ON BEHALF OF, PERSONS OR ENTITIES IN THE UNITED KINGDOM OR THE EUROPEAN ECONOMIC AREA OF THE UNITED KINGDOM, IT IS A QUALIFIED INVESTOR ACTING ON BEHALF OF, QUALIFIED INVESTOR ACTING ON BEHALF OF PERSONS OR ENTITIES IN THE UNITED KINGDOM.

THIS COMPANY PRESENTATION IS CONFIDENTIAL AND IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED IN ANY FORM OR FORWARDED OR FURTHER DISTRIBUTED TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE WHATSOEVER. ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS COMPANY PRESENTATION IN WHOLE OR PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS.

THE PROVISION OF THIS COMPANY PRESENTATION DOES NOT CONSTITUTE OR SHALL NOT BE RELIED UPON AS CONSTITUTING, THE GIVING OF INVESTMENT (OR OTHER) ADVICE BY THE COMPANY OR ANY OTHER SHAREHOLDERS, EMPLOYEES REPRESENTATIVES OR AFFILIATES THEREOF. NEITHER AVANGARD NOR ITS RESPECTIVE SUBSIDIARIES, ASSOCIATES, DIRECTORS, EMPLOYEES, AGENTS OR ADVISORS (SUCH DIRECTORS, EMPLOYEES, AGENTS OR ADVISORS BEING HEREAFTER REFERRED TO AS "REPRESENTATIVES"), MAKES ANY REPRESENTATIVES, AGENTS OR ADVISORS (SUCH DIRECTORS, EMPLOYEES, AGENTS OR ADVISORS BEING HEREAFTER REFERRED TO AS "REPRESENTATIVES"), MAKES ANY REPRESENTATION OR WARRANTY (EXPRESS OR IMPLIED) AS TO THE ADEQUACY, ACCURACY, REASONABLENESS OR COMPLETENESS OF THE INFORMATION CONTAINED IN THIS COMPANY PRESENTATION OR OF ANY ADDITIONAL INFORMATION, AND SUCH PARTIES OR ENTITIES EXPRESSLY DISCLAIM ANY AND ALL RESPONDED IN THIS COMPANY PRESENTATION OR OF ANY ADDITIONAL INFORMATION, AND SUCH PARTIES OR ENTITIES EXPRESSLY DISCLAIM ANY AND ALL RESPONDED ON OR RELATING TO THE ACCURACY OR SUFFICIENCY THEREOF, OR FOR ANY ERRORS OR OMISSIONS FROM, THIS COMPANY PRESENTATION OR ANY ADDITIONAL INFORMATION OR ANY ADDITIONAL INFORMATION OR BASED ON OR RELATING TO THE RECIPIENT'S RELIANCE OR USE OF THE RELIANCE OR USE BY ANY OF ITS ASSOCIATES OR REPRESENTATIVES ON OR OF THIS COMPANY PRESENTATION OR ANY ADDITIONAL INFORMATION, OR ANY ADDITIONAL INFORMATION, OR ANY ADDITIONAL INFORMATION OR ANY ADDITIONAL INFORMATION. OR ANY ADDITIONAL INFORMATION OR ANY ADDITIONAL INFORMATION OR ANY ADDITIONAL INFORMATION. OR ANY ADDITIONAL INFORMATION OR ANY ADDITIONAL INFORMATION OR ANY OTHER WRITTEN OR ORAL COMMUNICATIONS TRANSMITTED TO THE RECIPIENT OR ANY OF ITS ASSOCIATES OR REPRESENTATIVES OR ANY OTHER EVALUATION OF AN INVESTMENT IN THE COMPANY.

FORWARD LOOKING STATEMENTS

THIS COMPANY PRESENTATION INCLUDES STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE, "FORWARD LOOKING STATEMENTS". THESE FORWARD LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF FORWARD LOOKING TERMINOLOGY, INCLUDING THE TERMS "BELIEVES", "ESTIMATES", "ANTICIPATES", "EXPECTS", "INTENDS", "MAY", "WILL" OR "SHOULD" OR, IN EACH CASE THEIR NEGATIVE OR OTHER VARIATIONS OR COMPARABLE TERMINOLOGY. THESE FORWARD LOOKING STATEMENTS INCLUDE ALL MATTERS THAT ARE NOT HISTORICAL FACTS. THEY APPEAR IN A NUMBER OF PLACES THROUGHOUT THIS COMPANY PRESENTATION AND INCLUDE STATEMENTS REGARDING THE INTENTIONS, BELIEFS OR CURRENT EXPECTATIONS OF THE COMPANY. BY THEIR NATURE, FORWARD LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES BECAUSE THEY RELATE TO EVENTS AND DEPEND ON CIRCUMSTANCES THAT MAY OR MAY NOT OCCUR IN THE FUTURE. FORWARD LOOKING STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE. THE COMPANY'S ACTUAL PERFORMANCE, RESULTS OF OPERATIONS AND FINANCIAL CONDITION MAY DIFFER MATERIALLY FROM THE IMPRESSION CREATED BY THE FORWARD LOOKING STATEMENTS CONTAINED IN THIS COMPANY PRESENTATION.

SUBJECT TO ITS LEGAL AND REGULATORY OBLIGATIONS, AVANGARD EXPRESSLY DISCLAIMS ANY OBLIGATION TO UPDATE OR REVISE ANY FORWARD LOOKING STATEMENT CONTAINED HEREIN TO REFLECT ANY CHANGE IN EXPECTATIONS WITH REGARD THERETO OR ANY CHANGE IN EVENTS, CONDITIONS OR CIRCUMSTANCES ON WHICH ANY STATEMENT IS BASED. NEITHER TROIKA NOR ANY OF ITS RESPECTIVE AFFILIATES UNDERTAKE TO PROVIDE THE RECIPIENT HEREOF WITH ACCESS TO ANY ADDITIONAL INFORMATION OR TO UPDATE THIS COMPANY PRESENTATION OR TO CORRECT ANY INACCURACIES HEREIN WHICH MAY BECOME APPARENT.

ANY RECIPIENT OF THIS COMPANY PRESENTATION IS SOLELY RESPONSIBLE FOR ASSESSING AND KEEPING UNDER REVIEW THE BUSINESS, OPERATIONS, FINANCIAL CONDITION, PROSPECTS, CREDITWORTHINESS, STATUS AND AFFAIRS OF THE COMPANY. IN NO CIRCUMSTANCES SHALL THE DELIVERY OF THIS COMPANY PRESENTATION IMPLY THAT NO NEGATIVE CHANGE MAY OCCUR IN THE BUSINESS OF THE COMPANY AFTER THE DATE OF ISSUANCE OF THIS COMPANY PRESENTATION, OR ANY DATE OF AMENDMENT AND/OR ADDITION THERETO.

FINANCIAL INFORMATION AND ROUNDING

CERTAIN FINANCIAL INFORMATION CONTAINED IN THIS COMPANY PRESENTATION HAS BEEN EXTRACTED FROM THE COMPANY'S UNAUDITED MANAGEMENT ACCOUNTS AND FINANCIAL STATEMENTS PREPARED IN ACCORDANCE WITH UKRAINIAN ACCOUNTING STANDARDS ("UAS"). THE AREAS IN WHICH MANAGEMENT ACCOUNTS OR UAS FINANCIAL STATEMENTS DIFFER FROM INTERNATIONAL FINANCIAL REPORTING STANDARDS ("IFRS") AND/OR U.S. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES COULD BE SIGNIFICANT AND YOU SHOULD CONSULT YOUR OWN PROFESSIONAL ADVISORS AND/OR CONDUCT YOUR OWN DUE DILIGENCE FOR A FULLER UNDERSTANDING OF THE SIGNIFICANCE OF SUCH DIFFERENCES AND ANY IMPACT SUCH DIFFERENCES MAY HAVE ON THE RELEVANT FINANCIAL INFORMATION CONTAINED IN THIS COMPANY PRESENTATION. SOME NUMERICAL FIGURES INCLUDED IN THIS COMPANY PRESENTATION HAVE BEEN SUBJECT TO ROUNDING ADJUSTMENTS. ACCORDINGLY, NUMERICAL FIGURES SHOWN AS TOTALS IN CERTAIN TABLES MAY NOT BE AN ARITHMETIC AGGREGATION OF THE FIGURES THAT PRECEDED THEM.

CERTAIN INFORMATION PRESENTED HEREIN (INCLUDING MARKET DATA AND STATISTICAL INFORMATION) HAS BEEN OBTAINED FROM VARIOUS SOURCES WHICH THE COMPANY CONSIDERS TO BE RELIABLE. HOWEVER, THE COMPANY MAKES NO REPRESENTATION AS TO, AND ACCEPTS NO RESPONSIBILITY OR LIABILITY WHATSOEVER FOR, THE ACCURACY OR COMPLETENESS OF SUCH INFORMATION.

Avangard's Management Team



Nataliya Vasylyuk Chief Executive Officer



Iryna Marchenko Chief Financial Officer



Oksana Prosolenko Vice-president, Business Development


Avangard Overview


#1 egg and dry egg products producer and exporter in Ukraine in 2010

- ✓ 43% share in the industrial production of shell eggs (2009: 39%)
- ✓ 79% share in the production of dry egg products (2009: 52%)
- ✓ 52% share in exports of shell eggs (2009: 73%) and 97% share in exports of egg products (2009: 86%)
- Vertically integrated business model of 19 poultry farms for laying hens, 3 breeder farms, 9 growout farms, 6 fodder mills, 3 storage facilities and an egg processing plant
 - ✓ State-of-the-art integrated facilities, highly advanced technology and high bio-security standards
- Strong operational and financial performance
 - Consistent y-o-y increase in key operational and financial indicators
- Accomplishments in international capital markets
 - In May 2010, Avangard completed IPO of ordinary shares in the form of GDRs on LSE and raised \$208m (\$201m in net proceeds to the Company)
 - In October 2010, Avangard completed the issue of its \$200m debut senior unsecured 10% Notes due 29 October 2015 (\$193m in net proceeds to the Company)


Production of Shell Eggs, bln pieces

Production of Dry Egg Products, ths tons






Total Flock, mln heads



Key Financial Indicators, \$ mln



Avangard's Investment Highlights



2010 Trading Update



2010 Trading Update

Strong FY2010 operating results with sales up by 37% to \$440 mln primarily driven by increase in production volumes

Greater sales diversification via export and retail sales

Strict cost control resulted in moderate cost increase and stable margins

Timely implementation of investment projects


Minimization of related-party transactions

- Shell egg production volume increased by 22% to 4,420 million pieces (2009: 3,634 million pieces), largely as a result of the increase in poultry stock
- Production of egg products increased more than 4.5 times from 2.2 ths tons in 2009 to 10.2 ths tons in 2010 following full year of consolidation of Imperovo Foods results
- Over threefold increase of export volumes reaching the key milestone of 1 billion eggs and egg products in egg equivalent
- Key 2010 export markets for eggs and egg products included UAE, Jordan, Iraq, and Syria
- Share of direct sales to federal and local retail chains increased from 2% in 2009 to 16% in 2010
- Avangard's cost base was not materially impacted in 2010 by the high cost of grain in the Ukrainian market resulting from the reduction in grain yields following the regionwide draught
- Established policy of signing forward contracts for the purchase of corn and wheat and availability of own and leased storage capacity enabled the Company to secure the cost of key raw materials below market prices
- Construction of Avis and Chornobaivske is progressing on schedule
- On the back of the Eurobond covenants, the Company settled the related-party deposits, debt, receivables and payables by the end 2010

Outstanding Financial Indicators

Positive trend in top line and stable net profitability:


- Revenues increased by 37% compared to 2009, reaching \$439.7 mln which is largely explained by the increase in the total egg and egg products output and sale volumes
- EBITDA amounted to \$193.5 mln in 2010, a 27% increase versus 2009 backed up by solid revenues growth as well as stable cost of sales*
- Positive and growing bottom line with stable net margins
- Net debt of \$77.8m or 0.4x EBITDA 2010




EBITDA EBITDA margin 30% 114 39 2007 2008 2009 2010

EBITDA, \$m

Net Profit, \$m



Net Debt Position, \$m




Note: (*) 2009 EBITDA margin was higher than 2010 as a result of one-off item – waiver of \$23 mln of loans from related parties


2010 Revenue structure

- Shell egg segment remains the key segment in terms of revenues - 64% of total revenues
 - Strong increase by 16% in revenues from the segment resulting from higher volumes
- Egg products sales grew over 4 times
 - Growth is driven by volumes and strong demand from export markets

Revenue from external buyers dynamics, \$ mln



Drivers of the Revenue Growth in 2010, \$ mln



Diversified Customer Base


- Domestic wholesale remained key in 2010
- The Company has significantly increased direct sales to retail chains thus increasing operating margins
- Exports to MENA region played an important role
 - Saudi Arabia and UAE provided State support for food which boosted consumptions of eggs and egg derivative products
 - No exposure to turbulent markets like Lybia, Tunisia, and Egypt

Avangard's sales by distribution Channels, in egg equivalent (in volume terms)



Domestic wholesale





Egg products export

Country	2009	2009		2010	
,	USD (000s)	%	USD (000s)	%	
U.A.E	-	-	39 074	58,3	
Jordan	3 734	36,2	12 735	19,0	
Turkey	1 919	18,6	2 237	3,3	
Saudi Arabia	1 743	16,9	4 207	6,3	
Indonesia	1 619	15,7	4 993	7,4	
Korea	516	5,0	880	1,3	
Thailand	454	4,4	1 376	2,1	
Oman	144	1,4	196	0,3	
Others	186	1,8	1 362	2,0	
Total	10 315	100,0	67 059	100,0	

Shell eggs export

Country	2009		2010	
	USD (000s)	%	USD (000s)	%
Syria	5 923	22,6	4 511	31,0
Georgia	110	0,4	-	-
Iraq	19 609	74,7	9 019	62,1
Kazakhstan	312	1,2	559	3,8
Turkey	288	1,1	-	-
Moldova	-	-	295	2,0
U.A.E	-	-	147	1,0
Others	-	-	5	0,03
Total	26 241	100,0	14 535	100,0

Cost Structure


- Cost of sales increased in line with revenues by 36% in 2010 and was largely driven by growth in production volume
- Costs were not impacted by high cost of grain in 2010 because of existing hedging policy consisting of (i) signing prepaid contracts and (ii) build-up of significant stock of raw materials at seasonally low prices

Cost of Sales*

US\$'000	2009	2010
Raw materials	174,827	249,235
Salary and wages	14,953	16,394
Depreciation	11,641	12,165
Other	14,462	15,524
Total COGS	<u>215,883</u>	<u>293,318</u>

* Cost of finished goods only


Cost of Sales Structure



Sales, General and Administration

US\$'000	2009	2010
Salary and wages	3,904	4,731
Transportation	864	2,531
External services	1,535	3,248
Repairs and maintenance	73	70
Depreciation	643	471
Other	1,000	1,175
Total SG&A	<u>8,020</u>	<u>12,227</u>

Sales, General and Administration Costs Structure



2010 Financial Highlights – Balance Sheet


 Most of increase in total assets is attributable to 2x increase in inventory

- large purchases and stocking up in grain at attractive prices to mitigate price inflation of 1Q-2Q 2011
- Non-current biological assets value increased 174% resulting from an increase in total headcount including young laying hens
- Increase in inventory and non-current biological assets to support further production growth in 2011
- Non-current liabilities increased by 143% mainly as a result of \$200 mln. notes issue in October, 2010

US\$'000	2008	2009	2010	% change
CURRENT ASSETS	<u>536,927</u>	<u>430,000</u>	<u>562,992</u>	31%
Cash	5,878	1,727	183,065	
Trade Accounts Receivable	15,593	47,320	54,678	16%
Inventories	47,076	92,757	185,624	100%
NON-CURRENT ASSETS	<u>483,039</u>	<u>414,376</u>	<u>516,037</u>	25%
Non-Current Biological Assets	9,185	21,546	59,078	174%
Fixed Assets	368,264	375,426	396,236	6%
TOTAL ASSETS	<u>1,019,967</u>	<u>844,376</u>	<u>1,079,029</u>	28%
CURRENT LIABILITIES	<u>693,294</u>	<u>384,568</u>	<u>95,182</u>	-75%
Trade Accounts Payable	20,529	68,019	23,191	-66%
Other Payables	363,646	142,039	40,202	-72%
NON-CURRENT LIABILITIES	<u>208,169</u>	<u>99,023</u>	<u>237,628</u>	140%
TOTAL LIABILITIES	<u>901,463</u>	<u>483,591</u>	<u>332,810</u>	-31%
TOTAL EQUITY	<u>118,503</u>	<u>360,555</u>	<u>746,219</u>	107%
NET DEBT	<u>220,937</u>	<u>102,571</u>	<u>77,766</u>	-24%


Debt Structure

- Most of Avangard's debt is composed of long-term bonds issued in October, 2010
- Net Debt ratio reached 0.4x, a very attractive level compared to traded Ukrainian peers



US\$'000	2009	2010	% change
Total Debt	<u>265,038</u>	<u>261,011</u>	-2%
Long-term	92,117	231,646	151%
Short-term	172,921	29,356	-83%
Cash & Cash Equivalents	<u>1,727</u>	<u>183,065</u>	n.a.
<u>Deposits</u>	<u>156,421</u>	<u>0</u>	-100%
Financial Assistance Issued	<u>4,320</u>	<u>180</u>	-96%
Net Debt/(Net Cash)	<u>102,571</u>	<u>77,766</u>	-24%
Net Debt / EBITDA	0.7	0.4	
EBITDA/Interest expense	3.3	8.0	





Source: Bloomberg

2010 Financial Highlights – Cash Flow Statement

- 33% increase in operating profit before working capital changes
- Significant cash outflow from change in working capital results from
 - increase in inventory to mitigate grain price inflation
 - increase in VAT recoverable and prepaid, as a function of inventory increase
 - increase of prepayments to secure supply in the first months of 2011
 - decrease of accounts payables
 - minimization of related parties transactions
- The Company invested ca.\$70 mln in Avis and Chornobaivske projects in 2010
 - Both projects will be commissioned by the end of 2011

US\$'000	2008	2009	2010
Profit before income tax	75,869	134,837	185,012
Operating profit before working capital changes	109,546	121,310	163,418
(Increase)/decrease in net working capital	43,773	96,179	-298,817
Interest paid	-54,653	-51,781	-23,526
Income tax paid	-29	-48	-34
NET CASH GENERATED FROM/(USED IN) OPERATING ACTIVITIES	<u>98,637</u>	<u>165,660</u>	<u>-158,959</u>
Purchases of PP&E	-256,411	-3,370	-82,157
(Increase)/Decrease in bank deposits	-137,632	126,200	156,421
Net cash generated from/(used in) other investment activities	56,125	1,797	73,459
NET CASH GENERATED FROM/(USED IN) INVESTING ACTIVITIES	<u>-337,918</u>	<u>124,627</u>	<u>147,468</u>
NET CASH GENERATED FROM/(USED IN) FINANCING ACTIVITIES	<u>238,751</u>	-295,469	<u>192,855</u>
Effects of translation into presentation currency	1,856	1,097	0
NET INCREASE/(DECREASE) IN CASH	<u>1,326</u>	<u>-4,085</u>	<u>181,364</u>
Cash at the beginning of the year	4,460	5,786	1,701
Cash at the end of the year	5,786	1,701	183,065

Appendix: Supplementary Information



Income Statement

US\$'000	2008	2009	2010
REVENUE	<u>302,292</u>	<u>319,855</u>	<u>439,703</u>
Income from revaluation of biological assets at fair value	12,690	7,695	26,187
Cost of sales	-232,975	-220,407	-308,144
GROSS PROFIT	<u>82,007</u>	<u>107,143</u>	<u>157,746</u>
General administrative expenses	-7,932	-4,933	-7,168
Distribution expenses	-4,429	-3,086	-5,058
Other operating income/expenses, net	32,312	40,683	35,382
OPERATING PROFIT/(LOSS)	<u>101,958</u>	<u>139,807</u>	<u>180,902</u>
Financial income	26,897	41,180	34,058
Financial expenses	-52,986	-46,150	-29,948
PROFIT BEFORE TAX	<u>75,869</u>	<u>134,837</u>	<u>185,012</u>
Income tax expenses	1,414	-1,168	-254
PROFIT/(LOSS) FOR THE PERIOD	<u>77,283</u>	<u>133,669</u>	<u>184,758</u>

For the sake of convenience some rows were aggregated

Balance Sheet

US\$'000	2008	2009	2010
ASSETS			
Property, plant and equipment	368,264	375,426	396,236
Held-to-maturity investments	41	40	295
Non-current biological assets	9,185	21,546	59,078
Long-term deposits	49,351	504	0
Other non-current assets	56,198	16,860	60,428
Total non-current assets	<u>483,039</u>	<u>414,376</u>	<u>516,037</u>
Inventories	47,076	92,757	185,624
Taxes recoverable and prepaid, net	54,063	28,743	53,084
Current biological assets	47,935	44,910	44,705
Prepayments and other current assets, net	133,111	58,626	41,829
Trade accounts receivable, net	15,593	47,320	54,678
Short-term deposits	233,271	155,917	0
Cash and cash equivalents	5,878	1,727	183,065
Total current assets	<u>536,927</u>	<u>430,000</u>	<u>562,992</u>
TOTAL ASSETS	<u>1,019,967</u>	<u>844,376</u>	<u>1,079,029</u>
LIABILITIES AND EQUITY			
Share capital	644	644	836
Share premium	-	115,858	317,022
Retained earnings	168,151	300,107	482,328
Effect from translation into presentation currency	-56,698	-64,137	-64,587
Total equity attributable to shareholders of Avangard Group	<u>112,097</u>	<u>352,472</u>	<u>735,599</u>
Non-controlling interests	6,406	8,083	10,620
Total equity	<u>118,503</u>	<u>360,555</u>	<u>746,219</u>
Long-term loans	192,518	85,975	224,470
Long-term finance lease	8,502	6,142	6,372
Other non-current liabilities	7,149	7,136	6,786
Total non-current liabilities	<u>208,169</u>	<u>99,253</u>	<u>237,628</u>
Short-term interest bearing debt	204,605	164,043	30,475
Financial assistance received	104,151	8,535	0
Trade accounts payable	20,529	68,019	23,191
Other current liabilities and accrued expenses	364,009	143,971	41,516
Total current liabilities	<u>693,294</u>	<u>384,568</u>	<u>95,182</u>
TOTAL LIABILITIES AND EQUITY	<u>1,019,967</u>	<u>844,376</u>	<u>1,079,029</u>
Net Debt	220,937	<u>102,571</u>	<u>77,766</u>

For the sake of convenience some rows were aggregated